Pet2 Inhibitors
PET2 inhibitors refer to a class of chemical compounds that target a specific enzyme or protein function within biological systems. The designation PET2 suggests a particular molecular target, which could be involved in a critical biochemical pathway. Inhibitors, by definition, are substances that impede the activity of enzymes by attaching to them in a manner that hinders their interaction with substrates, effectively reducing the rate of the reactions they catalyze. This type of inhibition can be reversible or irreversible, depending on the nature of the inhibitor's binding to the enzyme. Reversible inhibitors typically form non-covalent bonds with enzymes, which allows them to dissociate readily, while irreversible inhibitors usually form covalent bonds that permanently inactivate the enzyme.
The specificity of PET2 inhibitors implies a focused mechanism of action, where these molecules are finely tuned to interact with the PET2 enzyme's active site or another critical region important for its function. The design of such inhibitors often involves a detailed understanding of the enzyme's structure and the dynamics of its interaction with natural substrates or cofactors. Researchers may employ various techniques, including X-ray crystallography, NMR spectroscopy, or computational modeling, to map the three-dimensional shape of the protein and identify potential binding pockets. Inhibitors might mimic the enzyme's natural substrates, thereby competing for the active site, or they could be designed to bind to allosteric sites-regions of the enzyme away from the active site-to induce conformational changes that diminish enzyme activity. In the development of PET2 inhibitors, chemists strive to optimize the balance between potency, selectivity, and desirable physicochemical properties to ensure that these compounds can efficiently and specifically interact with their intended target.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 can disrupt the PI3K/AKT signaling pathway. By inhibiting this pathway, it can lead to reduced phosphorylation and activation of downstream targets, which could potentially result in decreased functional activity of Pet2 by preventing its activation or translocation that may be PI3K-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound acts as a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. Through inhibition of MEK, PD98059 can impede the phosphorylation and activation of extracellular signal-regulated kinases (ERK1/2), which may be necessary for the full activation of Pet2, if Pet2’s function is modulated by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can lead to decreased activation of transcription factors and other proteins regulated by this kinase, potentially influencing Pet2’s activity if it is regulated by stress-activated signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. By blocking PI3K activity, it can inhibit the AKT signaling pathway, leading to decreased activation of downstream proteins and potentially reduced activity of Pet2 if Pet2 is involved in this signaling cascade. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 can disrupt various signaling pathways that depend on tyrosine phosphorylation, which could, in turn, lead to decreased activation or functionality of Pet2 if it is involved in such pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
This compound is a selective inhibitor of Rho-associated, coiled-coil containing protein kinase (ROCK). Y-27632 can inhibit the Rho/ROCK pathway, potentially affecting cytoskeletal dynamics and cellular processes that may be important for Pet2’s function if it involves actin filament assembly or cell motility. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can prevent the phosphorylation of c-Jun and the activation of AP-1 transcription factor, which may indirectly inhibit Pet2 if its activity is regulated via JNK-AP-1 signaling pathways. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A cell-permeable calcium chelator, BAPTA-AM can sequester intracellular calcium, potentially disrupting calcium-dependent signaling pathways. If Pet2 requires calcium signaling for its activation or function, BAPTA-AM could serve as an indirect inhibitor. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML7 is an inhibitor of myosin light chain kinase (MLCK), which is involved in the regulation of myosin-II activity in muscle and non-muscle cells. Inhibition of MLCK activity can affect cellular contraction and motility, possibly influencing Pet2 activity if it is associated with cellular contractile processes. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a pan-PKC inhibitor that can block the activity of various PKC isoforms. If Pet2 is regulated by PKC-mediated phosphorylation, the inhibition of PKC by Go6983 could lead to a decrease in Pet2’s functional activity. | ||||||